ORBIS (Open Research Biopharmaceutical Internships Support) – building bridges between academia and pharmaceutical industry to improve drug development

Journal of Medical Science

Sharon Davin¹  BożenaMichniak-Kohn²  Janina Lulek³  Emilia Jakubowska⁴  WojciechSmułek⁵  OlegSyarkevych⁶  GrzegorzGarbacz⁷  Lidia Tajber⁸  Clare Strachan⁹  Anne Juppo⁹  Aleksandra Dumicic^1,10  Piotr J. Rudzki^1,11 

[1] Applied Process Consulting Ltd., Dublin, Ireland;Center for Dermal Research and Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA;Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, Poznan, Poland;Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, Poznan;Institute of Technology and Chemical Engineering, Poznan University of Technology, Poznan, Poland;JSC Farmak, Kyiv, Ukraine;Physiolution GmbH, Greifswald, Germany;School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, College Green, Dublin 2;University of Helsinki, Division of Pharmaceutical Chemistry and Technology, Formulation and Industrial Pharmacy Unit, Helsinki, Finland;Zentiva k.s., Prague, Czech Republic;Łukasiewicz Research Network – Pharmaceutical Research Institute, Warsaw, Poland;

关键词: drug discovery and design;    pharmaceutical formulation;    research and development;    solid state materials;    pharmaceutical technology;    biomedical analysis;   

DOI  :  10.20883/medical.419

来源: DOAJ

【 摘 要 】

Open Research Biopharmaceutical Internships Support (ORBIS) is an international, Horizon 2020 project funded by Maria Skłodowska-Curie Actions, Research and Innovation Staff Exchange (RISE) programme. Six academic institutions and four pharmaceutical companies from seven countries cooperate with the aim to improve the preclinical pathway of medicine development through increased Research and Development (R&D) productivity, especially focusing on processes and technologies which address the challenge of poor drug bioavailability. The RISE scheme supports secondments, meaning that early stage and experienced researchers are sent to consortium partner institutions to advance studies on pharmaceutical preformulation, dosage forms and drug delivery systems and methods of biopharmaceutical evaluation. The ORBIS project enables secondees to gain news skills and develop their competences in an international and intersectoral environment, strengthening the human capital and knowledge synergy in the European pharmaceutical R&D sector.

【 授权许可】

Unknown